- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
FDA Clears New Electrocardiogram Suite of Algorithms and Analytics
Geared toward ambulatory use, the HeartKey Rhythm suite reportedly offers enhanced signal clarity and rhythm detection algorithms.
While noise contamination has been an issue with electrocardiograms (ECGs), a newly FDA-cleared suite of ECG algorithms may bolster signal clarity and detection of cardiac conditions.
Featuring unique signal processing technology, the HeartKey Rhythm suite facilitates noise reduction and improved data quality with ECGs, according to B-Secur, the developer of HeartKey Rhythm.1 The company maintains that the HeartKey Rhythm suite provides an antidote for challenges with ECG interpretation, citing a 2020 survey in which 53 percent of clinicians noted difficulty with interpreting remote ECGs.2
Featuring unique signal processing technology, the FDA-cleared HeartKey Rhythm suite facilitates noise reduction and improved data quality with ECGs, according to B-Secur, the developer of HeartKey Rhythm. (Image courtesy of B-Secur.)
"There is an ever-increasing reliance on ECG data collected outside of a controlled clinical environment," said Adrian Condon, the chief technology officer and co-founder of B-Secur. "Our breakthrough FDA cleared product, HeartKey Rhythm, significantly improves the ECG signal processing and rhythm recognition of ambulatory devices and platforms."
The company added that on-chip solutions with the HeartKey Rhythm suite can be utilized for patient wearable devices, further facilitating timely care for common cardiac conditions.
References
1. B-Secur. B-Secur elevates proactive, efficient cardiac care with FSA-cleared HeartKey Rhythm solution. PR Newswire. Available at: https://www.prnewswire.com/news-releases/b-secur-elevates-proactive-efficient-cardiac-care-with-fda-cleared-heartkey-rhythm-solution-302236210.html?tc=eml_cleartime . Published September 3, 2024. Accessed September 5, 2024.
2. Ding EY, Svennberg E, Wurster C, et al. Survey of current perspectives on consumer-available digital health devices for detecting atrial fibrillation. Cardiovasc Digit Health J. 2020;1(1):21-29.
Mammography Study Suggests DBT-Based AI May Help Reduce Disparities with Breast Cancer Screening
December 13th 2024New research suggests that AI-powered assessment of digital breast tomosynthesis (DBT) for short-term breast cancer risk may help address racial disparities with detection and shortcomings of traditional mammography in women with dense breasts.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Mammography News: FDA Grants Expanded 510(k) Clearance for AI-Powered SmartMammo Dx DBT Software
November 29th 2024Originally cleared by the FDA in 2021, the SmartMammo Dx software for digital breast tomosynthesis (DBT) can now be utilized with the Senographe Pristina mammography systems from GE HealthCare.
